RARE

Ultragenyx Pharmaceutical Inc. stock has been impacted by several key events in the past six months. The company reported a wider-than-expected loss in Q1 2026, but the stock increased as investors focused on reaffirmed revenue guidance and the path to profitability. The company reported losses in Q4 2025 and Q3 2025. Upcoming FDA PDUFA action dates for DTX401 and UX111 are significant catalysts. Phase 3 data for GTX-102 is expected in the second half of 2026. As of May 7, 2026, the stock was trading at $26.15, with a year-to-date increase of 13.6%, but a 12-month decrease of 27.38%.